← Back to Clinical Trials
Recruiting NCT06809933

NCT06809933 Exercise and Movement to Enhance Resiliency in Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06809933
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Gynecologic Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-03-24
Primary Completion 2031-08-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Digital Health Mobile AppVirtual Support GroupHealth Coaching

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-03-24 with a primary completion date of 2031-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a single-center, pilot, hybrid type 1 design implementation study to evaluate the feasibility and implementation of a personalized digital exercise program and a virtual support group to improve patient-centered outcomes in patients receiving treatment for gynecologic cancer receiving treatment at University of California, San Francisco.

Eligibility Criteria

Inclusion Criteria: 1. Age 18 years or older. 2. Newly diagnosed with a gynecological cancer (including ovarian tubal or peritoneal, uterine, cervical, vaginal, vulvar, and/or gestational trophoblastic neoplasia) and currently undergoing treatment chemotherapy, surgery, etc.). 3. Able to understand study procedures and to comply with study procedures for the entire length of the study. 4. Ability to understand a written informed consent document, and the willingness to sign it. 5. Eastern Cooperative Oncology Group (ECOG) status \< 4. 6. Willingness to participate and wear an activity tracker (FitBit). 7. Planning to start systemic treatment or currently receiving Cycle 1 of systemic treatment. Exclusion Criteria: 1. Medically ineligible or contraindications to exercise as determined by their oncologist; or contradiction to any other study-related procedure or assessment. 2. Cognitive or visual impairments that would limit participant's ability to utilize and interact with the DHT platform. Note: If a visually impaired participant has a caregiver who can help them use the DHT platform, the participant will not be excluded. 3. Existing performance of excessive physical activity (\>210 minutes per week of moderate to vigorous intensity exercise at baseline). 4. Existing enrollment in an exercise program or physical therapy program. 5. Inability to speak and read English.

Contact & Investigator

Central Contact

Nathalie Halley

✉ EMPOWER@ucsf.edu

📞 877-827-3222

Principal Investigator

Stephanie Cham, MD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06809933 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Gynecologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06809933 currently recruiting?

Yes, NCT06809933 is actively recruiting participants. Contact the research team at EMPOWER@ucsf.edu for enrollment information.

Where is the NCT06809933 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT06809933 clinical trial?

NCT06809933 is sponsored by University of California, San Francisco. The principal investigator is Stephanie Cham, MD at University of California, San Francisco. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology